The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EMA approval of lenalidomide plus rituximab for adult patients with R/R FL

Jan 6, 2020

The Lymphoma Hub has recently covered news on the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, issuing a positive opinion for the approval of lenalidomide plus rituximab (R2) as a treatment for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). You can read it here.

On the 20th of December 2019, the R2 combination was approved by the EMA, based on the positive data from multi-center phase III studies AUGMENT (NCT01938001) and MAGNIFY (NCT01996865).1 

You can read the Lymphoma Hub’s coverage of the AUGMENT study, watch an interview with Marek Trněný discussing the post-hoc analysis of the data in the elderly population, and Mathias Rummel discussing the MAGNIFY trial.

  1. Bristol-Myers Squibb. Bristol-Myers Squibb receives European Commission approval for Revlimid® (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated follicular lymphoma. December 20, 2019. Published; December 20, 2019, [Accessed January 3 2020]